DelveInsight’s, “Biliary Tract Cancers Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers (BTCs) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Biliary Tract Cancers Emerging drugs, the Biliary Tract Cancers pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Biliary Tract Cancers pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Biliary Tract Cancers Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Biliary Tract Cancers clinical trials studies, Biliary Tract Cancers NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancers collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Biliary Tract Cancers Pipeline Report
- DelveInsight’s Biliary Tract Cancers Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Biliary Tract Cancers.
- The leading Biliary Tract Cancers Companies includes Eli Lilly and Company, Merck Sharp & Dohme Corp., InnoPharmax Inc., Shanghai Miracogen Inc., AstraZeneca, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Lee’s Pharmaceutical Limited, RemeGen Co., Ltd., Zymeworks Inc., BeiGene, Ltd., Hoffmann-La Roch, Eisai Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, Adherex Technologies, Inc., and others.
- Promising Biliary Tract Cancers pipeline therapies includes M7824, Atezolizumab, Bevacizumab, Lenvatinib, ZW25 (Zanidatamab), Gemcitabine, Cisplatin, S-1/Gemcitabine, Ramucirumab, Nivolumab, TH-302 monotherapy, and others.
- The Biliary Tract Cancers companies and academics are working to assess challenges and seek opportunities that could influence biliary tract cancer R&D. The Biliary Tract Cancers pipeline therapies under development are focused on novel approaches to treat/improve Asthma.
Request a sample and discover the recent breakthroughs happening in the Biliary Tract Cancers Pipeline landscape @ Biliary Tract Cancers Pipeline Outlook Report
Biliary Tract Cancers Overview
Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation.
Recent Developmental Activities in the Biliary Tract Cancer Treatment Landscape
- In January 2022, orphan drug designation (ODD) was received for Silmitasertib for the treatment of biliary tract cancer, a rare, malignant disease for which there are no effective therapies.
- In 2022, Genome and Company and Merck (MSD) have signed a clinical trial collaboration and supply agreement to analyse GEN-001 plus Keytruda (pembrolizumab) in a Phase II clinical trial to treat biliary tract cancer.
- In November 2020, orphan designation was granted by the European Commission for Zanidatamab (also known as ZW25) for the treatment of gastric cancer.
For further information, refer to the detailed Biliary Tract Cancers Drugs Launch, Biliary Tract Cancers Developmental Activities, and Biliary Tract Cancers News, click here for Biliary Tract Cancers Ongoing Clinical Trial Analysis
Biliary Tract Cancers Emerging Drugs Profile
- Durvalumab: AstraZeneca
Durvalumab is an anticancer antibody that works to promote the anti-tumor responses mediated by immune cells. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). A randomized, double-blind placebo controlled, multi-regional phase III are being conducted to evaluate the effect of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers. This study is expected to get completed by July 2022.
- MRG 002: Miracogen
MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
- Zanidatamab: Zymeworks
Zanidatamab, is a HER2-targeted bispecific antibody developed by Zymeworks. Zanidatamab binds to two distinct sites on HER2, a protein expressed on many types of cancer cells. This results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. Zanidatamab have received Orphan Drug designation for the treatment of biliary tract and gastric cancers in the United States. Zymeworks is currently conducting phase II study of Zanidatamab (ZW25) plus first-line combination chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC).
- AZD5305: Astra Zeneca
AZD5305 is a PARP-1 selective inhibitor. In cancer treatment, PARP inhibitors stop the PARP from doing its repair work in cancer cells and the cell dies. A phase I/IIa, open-label, multicenter trials are under progress to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of ascending doses of AZD5305 as monotherapy and in combination with Anti-cancer agents in patients with advanced solid malignancies.
- Ramucirumab: Eli Lilly and Company
Ramucirumab, an immunotherapy drug, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. Ramucirumab inhibits ligand-stimulated activation of VEGF2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Eli Lily and Company is conducting Phase I clinical trials to study Ramucirumab plus Pembrolizumab in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, non-small cell lung cancer, transitional cell carcinoma of the urothelium, or biliary tract cancer
Biliary Tract Cancers Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Asthma. The companies which have their biliary tract cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
Find out more about the Biliary Tract Cancers Pipeline Segmentation, Therapeutics Assessment, and Biliary Tract Cancers Emerging Drugs @ Biliary Tract Cancers Treatment Landscape
Scope of the Biliary Tract Cancers Pipeline Report
- Coverage- Global
- Biliary Tract Cancers Companies- Eli Lilly and Company, Merck Sharp & Dohme Corp., InnoPharmax Inc., Shanghai Miracogen Inc., AstraZeneca, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Lee’s Pharmaceutical Limited, RemeGen Co., Ltd., Zymeworks Inc., BeiGene, Ltd., Hoffmann-La Roch, Eisai Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, Adherex Technologies, Inc., and others.
- Biliary Tract Cancers Pipeline Therapies- M7824, Atezolizumab, Bevacizumab, Lenvatinib, ZW25 (Zanidatamab), Gemcitabine, Cisplatin, S-1/Gemcitabine, Ramucirumab, Nivolumab, TH-302 monotherapy, and others.
- Biliary Tract Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Biliary Tract Cancers Pipeline Companies and Therapies, click here @ Biliary Tract Cancers Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Biliary tract cancer Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Biliary tract cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Durvalumab: AstraZeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MRG 002: Miracogen
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- AZD5305: Astra Zeneca
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Ramucirumab: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Inactive Products
- Biliary tract cancer Key Companies
- Biliary tract cancer Key Products
- Asthma- Unmet Needs
- Asthma- Market Drivers and Barriers
- Asthma- Future Perspectives and Conclusion
- Biliary tract cancer Analyst Views
- Biliary tract cancer Key Companies
- Appendix
Got Queries? Find out the related information on Biliary Tract Cancers Mergers and acquisitions, Biliary Tract Cancers Licensing Activities @ Biliary Tract Cancers Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/